Physician profile
Bassem Arab
NPI 1780116061
$2,838.43
in general payments reported to CMS, 2019-2025
19 companies · $983 in 2025
The $983 reported for 2025 was more than what 77% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $123 · 2023: $481 · 2024: $1,253 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Education: $36.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.96 |
| Education | $36.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.33 | 2023-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $384.86 | 2023-2025 | Jynarque |
| Travere Therapeutics, INC. | $313.43 | 2022-2025 | |
| Aurinia Pharma U.S., INC. | $251.11 | 2022-2024 | Lupkynis |
| Amgen INC. | $242.82 | 2023-2025 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $183.76 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $181.43 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $108.70 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $96.45 | 2022-2025 | Benlysta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $92.24 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $84.62 | 2023-2025 | Rayaldee |
| Kyowa Kirin, INC. | $81.17 | 2023-2025 | Crysvita |
| Cormedix INC. | $67.97 | 2024 | Defencath |
| Vifor Pharma, INC. | $66.28 | 2023-2025 | Veltassa, Korsuva |
| Ascendis Pharma Endocrinology INC | $49.31 | 2025 | Yorvipath |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $37.70 | 2025 | |
| Horizon Therapeutics Plc | $32.21 | 2023 | Krystexxa |
| Ultragenyx Pharmaceutical INC. | $17.75 | 2023 | Crysvita |
| Lilly USA, LLC | $13.29 | 2023 | Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bassem Arab listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.